Short and long‐term management of haemophilia A patient requiring heart valve surgery

Zatorska, Karina; Orłowska−Baranowska, Ewa; Abramczuk, Elżbieta; Kuśmierczyk, Mariusz; Greszata, Lidia; Grabowski, Maciej; Stępińska, Janina; Baran, Beata; Windyga, Jerzy

doi:10.1111/j.1365-2516.2012.02812.x

Cited by 10 publications

(15 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thereafter, standard recommendations endorse maintenance of trough factor levels of 50% until wound healing is nearly complete (postoperative day 10–14). 102 In PWH with inhibitors, unless the inhibitor titer is low (≤5 Bethesda units/mL) or there is an opportunity to eradicate the inhibitor before operation, bypassing agents substitute for clotting factor replacement (Table 2 ). 41 In addition to factor replacement therapies, adjunctive use of tranexamic acid for postoperative hemostatic coverage in PWH is an option.…”

Section: Cardiovascular Conditions Requiring Operations In People Witmentioning

confidence: 99%

“… 130 Experience with annuloplasty in this population is very limited, with only 2 case reports identified in the literature. 102 , 111 Individuals without hemophilia who undergo annuloplasty typically receive anticoagulation for 3 months after the procedure, similar to those undergoing bioprosthetic valve replacement. 102 Whether PWH require similar anticoagulation after annuloplasty is uncertain.…”

Section: Cardiovascular Conditions Requiring Operations In People Witmentioning

confidence: 99%

See 1 more Smart Citation

Consensus Review of the Treatment of Cardiovascular Disease in People With Hemophilia A and B

Ferraris

Boral

Cohen

et al. 2015

Cardiology in Review

104

View full text Add to dashboard Cite

With advances in care, increasing numbers of people with hemophilia (PWH) achieve near-normal life expectancies and present with typical age-related cardiovascular conditions. Evidence-based guidelines for medical or surgical management of cardiovascular conditions in individuals with hemophilia are limited. Published recommendations exist for the management of some common cardiovascular conditions (eg, ischemic heart disease, atrial fibrillation), but identifying optimal strategies for anticoagulant or antithrombotic therapy constitutes the primary challenge of managing nonoperative cardiovascular disease (CVD) in PWH. In general, as long as factor concentrates or other hemostatic therapies maintain adequate hemostasis, the recommended medical and surgical management of CVD in PWH parallels that in individuals without hemophilia. The presence of factor inhibitors complicates hemophilia management. Published outcomes of CVD treatment in PWH are similar to those in the general population. Specific knowledge about factor replacement, factor inhibitors, and disease-specific treatment distinguishes the cardiovascular care of PWH from similar care of individuals without this rare bleeding disorder. Furthermore, a multidisciplinary approach incorporating a hematologist with an onsite coagulation laboratory, ideally associated with a hemophilia treatment center, is integral to the management of CVD in PWH.

show abstract

Section: Cardiovascular Conditions Requiring Operations In People Witmentioning

confidence: 99%

Section: Cardiovascular Conditions Requiring Operations In People Witmentioning

confidence: 99%

Consensus Review of the Treatment of Cardiovascular Disease in People With Hemophilia A and B

Ferraris

Boral

Cohen

et al. 2015

Cardiology in Review

104

View full text Add to dashboard Cite

show abstract

“…Several authors have described cardiac surgery in patients with hemophilia A and B, including on‐pump coronary artery bypass grafting (CABG), 3‐5 off‐pump CABG, 6 aortic valve replacement (AVR), 3,7‐10 and mitral valve repair 3,11,12 . In general, these patients had good survival outcomes, though many developed bleeding complications 3,4 .…”

Section: Discussionmentioning

confidence: 99%

“…Reports are widely varied regarding whether recombinant factors should be bolused or given as continuous infusions to achieve the desired level. The use of antiplatelet agents, chemical DVT prophylaxis, and systemic anticoagulation (in the case of valve repair or replacement) is also inconsistent, though all have been reported with good outcomes in select patients 3,4,6,8‐10,12 …”

Section: Discussionmentioning

confidence: 99%

Robotic mitral valve repair in a type B hemophiliac

et al. 2020

View full text Add to dashboard Cite

Hemophilia B is a rare X-linked recessive disorder that places surgical patients at an increased risk of bleeding. Patients with hemophilia are now achieving near-normal life expectancies and therefore the number of these patients requiring cardiac surgery due to the development of age-related cardiovascular disease may increase.We present the case of a young male with hemophilia B who was diagnosed with severe symptomatic mitral regurgitation and underwent successful robotic mitral valve repair. To our knowledge, this is the first report of a patient with hemophilia B who underwent robotic mitral valve repair. K E Y W O R D S replacement, valve repair

show abstract

“…Data collection and research efforts are underway to increase our knowledge of the prevalence and management of co‐morbidities in the ageing haemophilia population . However, there are no evidence‐based guidelines for managing co‐morbidities in elderly patients with haemophilia, which often require drugs that interfere with haemostasis, enhance the bleeding tendency and require more intensive replacement therapy.…”

Section: Discussionmentioning

confidence: 99%

Co‐morbidities and bleeding in elderly patients with haemophilia—A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH)

et al. 2017

View full text Add to dashboard Cite

show abstract

Short and long‐term management of haemophilia A patient requiring heart valve surgery

Cited by 10 publications

References 9 publications

Consensus Review of the Treatment of Cardiovascular Disease in People With Hemophilia A and B

Consensus Review of the Treatment of Cardiovascular Disease in People With Hemophilia A and B

Robotic mitral valve repair in a type B hemophiliac

Co‐morbidities and bleeding in elderly patients with haemophilia—A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH)

Contact Info

Product

Resources

About